Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement

Laupacis, Andreas; Brown, Janice; Costello, Brenda; Delage, Gilles; Freedman, John; Hume, Heather; King, Susan; Kleinman, Steve; Mazzulli, Tony; Wells, George

doi:10.1046/j.1537-2995.2001.41040560.x

Cited by 75 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…der Applikation von seronegativem Blut sind widersprüchlich. Einerseits wird beschrieben, dass die Leukozytendepletion der Verwendung HCMV-seronegativer, nicht leukozytenreduzierter Blutkomponenten äquivalent ist [55,62,63,116,119,[139][140][141][142][143][144][145][146]. Neue Studienergebnisse belegen, dass frisch serokonvertierte Spender die höchsten Viruskonzentrationen im Verlauf einer HCMV-Infektion haben.…”

Section: Möglichkeiten Zur Abtrennung Und Inaktivierung Von Infektionunclassified

Humanes Cytomegalievirus (HCMV)

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

Section: Möglichkeiten Zur Abtrennung Und Inaktivierung Von Infektionunclassified

Humanes Cytomegalievirus (HCMV)

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…In Canada, the infectious disease risks of transfusion are minimized through multiple steps, including blood collection from volunteer unpaid donors, donor interview and selection procedures, careful aseptic technique procedures for collection and infusion, diversion of the first 40 mL of blood collected into a diversion pouch, donor screening by serological and other tests ( (11), and viral inactivation procedures included in the manufacturing of plasma-derived products (Table 2) (12)(13)(14)(15).…”

mentioning

confidence: 99%

Transfusion and Risk of Infection in Canada: Update 2005

MacDonald¹,

Scott²,

Giulivi³

2005

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

In Canada and other countries, many steps are taken to minimize the risk of infection through the transfusion of blood or blood products (1). However, the infection risk can never be zero because these are biological products that are taken from living donors who are never 'germ free' (2). This is in contrast to drugs that can be manufactured de novo under sterile conditions in a laboratory. The present note provides an update on transfusion infection risks in Canada. It replaces the 2004 note (3) and may be helpful to practitioners in discussions with patients and parents toward obtaining informed consent before blood or blood product administration.

show abstract

“…In Canada, the infectious disease risks of transfusion are minimized through multiple steps, including: blood collection from volunteer unpaid donors, donor interview and selection procedures, donor screening by serological and other tests ( manufacturing of plasma-derived products (Table 2) (11)(12)(13)(14).…”

mentioning

confidence: 99%

“…Heat inactivation is effective against a wide range of viruses, including WNV, hepatitis A virus and parvovirus (14). The leukocyte reduction technique that is used by Canadian Blood Services and Héma-Québec to further improve the safety of the blood supply also reduces the infection transmission risk, particularly for cytomegalovirus (CMV) (13). Table 3 identifies specific inactivation steps in the manufacture of different plasma-derived products that decrease viral infection risks.…”

mentioning

confidence: 99%

“…For CMV seronegative recipients, the risk of CMV infection in solid organ transplant recipients and in bone marrow transplant recipients is 2% to 3% and 20% to 50%, respectively. This risk can be decreased with selection for seronegative donors and/or the use of leukocyte depletion filters, eg, the estimated risk for a bone marrow transplant recipient is only 2.4 % using a leukocyte depletion filter (13).…”

mentioning

confidence: 99%

See 1 more Smart Citation